Table 2.

Univariate Analysis of Clinician Decision-Making and RAI Use

		Number (%)	Proportion treated with RAI at hospital (mean % ± S.D.)	P Value
Number of provider involved in decision making about use of RAI				0.201
3 or more		105 (20%)	47.88 ± 19.00
2		332 (63%)	45.86 ± 21.35
1		90 (17%)	42.48 ± 22.52
Number of providers administering RAI				<0.001
3 or more		240 (46%)	47.47 ± 19.21
2		143 (27%)	48.76 ± 19.46
1		102 (20%)	44.55 ± 25.01
0		36 (7%)	29.28 ± 22.63
Access to tumor board				0.011
Yes		395 (71%)	47.54 ± 20.50
No		158 (29%)	42.55 ± 22.04
Frequency of tumor board				0.188
Weekly		166 (42%)	49.42 ± 19.61
Twice a month		73 (19%)	48.15 ± 19.14
Once a month		134 (34%)	44.31 ± 22.57
Other		20 (5%)	45.91 ± 20.22
Same day visits with other providers				0.791
Yes		110 (20%)	45.46 ± 19.66
No		446 (80%)	46.06 ± 21.55
Primary decision maker on whether or not to administer RAI				0.004
Surgeon		87 (16%)	42.29 ± 21.57
Endocrinologist		374 (69%)	45.42 ± 20.37
NM/Radiol/Other		83 (15%)	52.50 ± 23.05
Primary decision maker on dose of RAI				0.894
Surgeon		4 (1%)	41.22 ± 18.63
Endocrinologist		232 (45%)	46.27 ± 20.26
NM/Radiol/Other		282 (54%)	46.14 ± 21.91
Primarily administers RAI				0.192
Surgeon		0 (0%)
Endocrinologist		165 (31%)	44.18 ± 21.72
NM/Radiol/Other		361 (69%)	46.80 ± 21.22
Surgeon involved in RAI decision making				0.591
Yes		414 (74%)	45.73 ± 21.20
No		143 (26%)	46.83 ± 21.07

RAI = radioactive iodine, NM = nuclear medicine provider